AIM ImmunoTech green-lit by the FDA for its trial to treat coronavirus patients with cancer

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive the FDA has approved the first human trial of the company’s lead drug Ampligen …

Be the first to comment

Leave a Reply

Your email address will not be published.